Definium Therapeutics CFO Brandi Roberts Receives 125,000-Share Award

What Happened

• Brandi Roberts, Chief Financial Officer of Definium Therapeutics (DFTX), was granted 125,000 common shares on September 14, 2026. The filing reports an acquisition price of $0.00 (i.e., a compensation award), so no cash was paid.
• These shares represent the third tranche of performance share units (PSUs) originally granted June 2, 2025, and remain subject to vesting based on continued employment through June 2, 2028 and on achievement of specified clinical and regulatory milestones.

Key Details

• Transaction date: 2026-09-14; price reported: $0.00 per share; total reported value: $0 (compensation award).
• Shares owned after transaction: not specified in the filing.
• Footnote F1: These 125,000 shares are the third tranche of PSUs from the 6/2/2025 award and vest only if milestones are met and Roberts remains employed through 6/2/2028.
• Footnote F2: The filing also notes 918 shares acquired under Definium’s 2024 Employee Share Purchase Plan on August 17, 2026 (separately acquired).
• Filing timeliness: transaction and Form 4 are dated 2026-09-14 (no late filing indicated in the document).

Context

• Performance share units are contingent awards: they become actual shares only if performance conditions and employment-vesting requirements are satisfied. These grants are compensation, not open-market purchases or sales, and do not necessarily reflect immediate insider buying or selling intent.
• For retail investors, PSUs indicate potential future dilution if milestones are met and units vest; they are common tools for executive compensation tied to company milestones.